To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Trial · NCT01496313
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomized Period (up to 14 Months) | STARTED | Randomized Period: Vandetanib 150 mg | 40 | |
| Randomized Period (up to 14 Months) | STARTED | Randomized Period: Vandetanib 300 mg | 41 | |
| Randomized Period (up to 14 Months) | STARTED | Open-label Period: Vandetanib 100 mg | 0 | |
| Randomized Period (up to 14 Months) | STARTED | Open-label Period: Vandetanib 150 mg | 0 | |
| Randomized Period (up to 14 Months) | STARTED | Open-label Period: Vandetanib 200 mg | 0 | |
| Randomized Period (up to 14 Months) | STARTED | Open-label Period: Vandetanib 300 mg | 0 | |
| Randomized Period (up to 14 Months) | COMPLETED | Randomized Period: Vandetanib 150 mg | 35 | |
| Randomized Period (up to 14 Months) | COMPLETED | Randomized Period: Vandetanib 300 mg | 26 | |
| Randomized Period (up to 14 Months) | COMPLETED | Open-label Period: Vandetanib 100 mg | 0 | |
| Randomized Period (up to 14 Months) | COMPLETED | Open-label Period: Vandetanib 150 mg | 0 | |
| Randomized Period (up to 14 Months) | COMPLETED | Open-label Period: Vandetanib 200 mg | 0 | |
| Randomized Period (up to 14 Months) | COMPLETED | Open-label Period: Vandetanib 300 mg | 0 | |
| Randomized Period (up to 14 Months) | NOT COMPLETED | Randomized Period: Vandetanib 150 mg | 5 | |
| Randomized Period (up to 14 Months) | NOT COMPLETED | Randomized Period: Vandetanib 300 mg | 15 | |
| Randomized Period (up to 14 Months) | NOT COMPLETED | Open-label Period: Vandetanib 100 mg | 0 | |
| Randomized Period (up to 14 Months) | NOT COMPLETED | Open-label Period: Vandetanib 150 mg | 0 | |
| Randomized Period (up to 14 Months) | NOT COMPLETED | Open-label Period: Vandetanib 200 mg | 0 | |
| Randomized Period (up to 14 Months) | NOT COMPLETED | Open-label Period: Vandetanib 300 mg | 0 | |
| Open-Label Period (Month 14 to 2 Years) | STARTED | Randomized Period: Vandetanib 150 mg | 0 | |
| Open-Label Period (Month 14 to 2 Years) | STARTED | Randomized Period: Vandetanib 300 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01496313/flow